Close Menu

NEW YORK – Boston-based Takeda Pharmaceuticals USA said Friday that it has entered into an exclusive partnership to optimize an MiTest Health personalized risk and outcome prediction tool for widespread use in patients with Crohn's disease.

The predictive tool was developed by MiTest in 2014 and has been validated in a cohort of adult patients with Crohn's disease, but so far it has been used on a limited basis in clinical settings.

Takeda said it will work with MiTest to provide support in scaling up the tool to expand its reach among gastroenterologists and their patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.